Abstract
Abuse-deterrent opioid formulations are receiving renewed interest in light of the increasing legitimate medical use of prescription opioids for the adequate treatment of pain. Unfortunately, there is an inevitable associated potential for misuse, diversion, and abuse. The challenges of deterrence are significant: opioid abusers are a heterogeneous population; studies on drug “liking” and opioid “attractiveness” are informative, but mainly rely on reports from users who are not reliable respondents; drug “liking” scores are useful, but it is unclear how much drug “liking” must be reduced in order to achieve an actual reduction in abuse levels; and the most popular drugs among opioid abusers appear to be those that meet a complex combination of both positive and negative criteria including things like availability, pricing, and how easily the drug’s illicit use can be concealed. Several abuse-deterrent formulations have been introduced or are in development. Epidemiological studies will have to be conducted to evaluate their effectiveness. Although there are currently more questions than answers, such products are clearly of medical and societal importance.
Keywords: Opioids, opioid abuse, opioid misuse, abuse-deterrent opioids, abuse-resistant opioids, pain, availability, pricing, drug, effectiveness.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse- Deterrent Formulations
Volume: 18 Issue: 37
Author(s): Joseph V. Pergolizzi, Robert B. Raffa, Jason S. Pergolizzi and Robert Taylor
Affiliation:
Keywords: Opioids, opioid abuse, opioid misuse, abuse-deterrent opioids, abuse-resistant opioids, pain, availability, pricing, drug, effectiveness.
Abstract: Abuse-deterrent opioid formulations are receiving renewed interest in light of the increasing legitimate medical use of prescription opioids for the adequate treatment of pain. Unfortunately, there is an inevitable associated potential for misuse, diversion, and abuse. The challenges of deterrence are significant: opioid abusers are a heterogeneous population; studies on drug “liking” and opioid “attractiveness” are informative, but mainly rely on reports from users who are not reliable respondents; drug “liking” scores are useful, but it is unclear how much drug “liking” must be reduced in order to achieve an actual reduction in abuse levels; and the most popular drugs among opioid abusers appear to be those that meet a complex combination of both positive and negative criteria including things like availability, pricing, and how easily the drug’s illicit use can be concealed. Several abuse-deterrent formulations have been introduced or are in development. Epidemiological studies will have to be conducted to evaluate their effectiveness. Although there are currently more questions than answers, such products are clearly of medical and societal importance.
Export Options
About this article
Cite this article as:
V. Pergolizzi Joseph, B. Raffa Robert, S. Pergolizzi Jason and Taylor Robert, Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse- Deterrent Formulations, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582379
DOI https://dx.doi.org/10.2174/138161212803582379 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Characterization and Preclinical Perspectives of Organic Small Molecule Drug Metabolites in Drug-drug Interactions
Current Organic Chemistry Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology The Resting-State Functional Connectivity of the Default Mode Networks in Patients With Obstructive Sleep Apnea-Hypopnea Syndrome
CNS & Neurological Disorders - Drug Targets Computational and Experimental Approaches to Design Inhibitors of Amylin Aggregation
Current Drug Targets Commentary
CNS & Neurological Disorders - Drug Targets Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Preface (Walter H. Kaye)
Current Drug Targets - CNS & Neurological Disorders Ultrasound Image Based Tumor Classification via Deep Polynomial Network and Multiple Kernel Learning
Current Medical Imaging Antifreeze Proteins from Diverse Organisms and their Applications: An Overview
Current Protein & Peptide Science Interferon-γ-Induced Neurotoxicity of Human Astrocytes
CNS & Neurological Disorders - Drug Targets Design and Evaluation of a Modulated TENS Stimulation in Medical Pain Therapy
Current Signal Transduction Therapy Designing Phage Therapeutics
Current Pharmaceutical Biotechnology Editorial: Signaling Molecules as Biomarkers and Therapeutic Targets for Alzheimer's Disease: A New Perspective
Current Alzheimer Research Extracellular Vesicles in the Treatment of Parkinson’s Disease: A Review
Current Medicinal Chemistry Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets Nanotechnology can Provide Therapeutic Agent by Targeting Molecular Structures of SARS-CoV-2 (COVID-19): A Mini-Review
Letters in Drug Design & Discovery Impaired Cognitive Function is Associated with Motor Function and Activities of Daily Living in Mild to Moderate Alzheimer's Dementia
Current Alzheimer Research Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety
Current Pharmaceutical Design Prevalence of Dilated Cardiomyopathy in HIV-Infected African Patients Not Receiving HAART: A Multicenter, Observational, Prospective, Cohort Study in Rwanda
Current HIV Research